GSK573719 62.5 — Competitive Intelligence Brief

GSK573719 62.5 (GSK573719 62.5) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory / Pulmonology.

phase 3 Long-acting muscarinic antagonist (LAMA) Muscarinic M3 receptor Respiratory / Pulmonology Small molecule

Target snapshot

GSK573719 62.5 (GSK573719 62.5) — GlaxoSmithKline. GSK573719 is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in airway smooth muscle to promote bronchodilation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GSK573719 62.5 TARGET	GSK573719 62.5	GlaxoSmithKline	phase 3	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor
Budesonide/formoterol and tiotropium	Budesonide/formoterol and tiotropium	Brian J Lipworth	marketed	Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
LABA/LAMA or Placebo inhalation	LABA/LAMA or Placebo inhalation	Shanghai Pulmonary Hospital, Shanghai, China	marketed	LABA/LAMA combination bronchodilator	Beta-2 adrenergic receptor and muscarinic M3 receptor
Budesonide/Glycopyrronium/Formoterol Fumarate	Budesonide/Glycopyrronium/Formoterol Fumarate	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol); muscarinic M3 receptor (glycopyrronium)
Tiotropium & olodaterol	Tiotropium & olodaterol	University of Dundee	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
Tiotropium/Formoterol	Tiotropium/Formoterol	Neutec Ar-Ge San ve Tic A.Ş	marketed	Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (tiotropium); Beta-2 adrenergic receptor (formoterol)
umeclidinium 62.5 µg and vilanterol 25 µg	umeclidinium 62.5 µg and vilanterol 25 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting anticholinergic and long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

1. GlaxoSmithKline · 9 drugs in this class
2. AstraZeneca · 3 drugs in this class
3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
4. Chiesi Farmaceutici S.p.A. · 1 drug in this class
5. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
6. Lupin, Inc. · 1 drug in this class
7. Sanofi · 1 drug in this class